A United Kingdom nationally representative survey of public attitudes towards pharmacogenomics DOI Creative Commons
Emma Magavern, Gabriel Marengo,

Chujan Sivathasan

и другие.

QJM, Год журнала: 2025, Номер unknown

Опубликована: Янв. 31, 2025

Abstract Background Variation in DNA is known to contribute medication response, impacting both medicine effectiveness and incidence of adverse drug reactions (ADRs). However, clinical implementation pharmacogenomics (PGx) has been slow, the views public are not well understood. Aim To assess UK national attitudes around pharmacogenetics. Design Methods The survey was co-designed with Participant Panel at Genomics England data were collected by National Centre for Social Research, using its nationally representative panel adults. Multivariable logistic regression analyses used analyse relationships between selected reported variables, controlled age sex. Results response rate 58%. Two thousand seven hundred nineteen responses obtained. Most respondents (59%) had experienced either no benefit or a side effect. Forty-five per cent having 46% effect, female more likely be groups (P < 0.0001). Despite variability interindividual being understood (89%), involvement predicting risk effect (understood 52% 48%, respectively). Eighty-nine would complete PGx test, 91% wanting direct access this information. Eighty-five adults think that NHS should offer those regularly taking many medicines. Respondents worried overall about misuse compared other routine medical data. Experience prescription impacted on who prescribed almost twice as want test any reason. Conclusion experience working them ADRs. There high level understanding variable but relatively low awareness role genetics plays variability. have results, form testing. Importantly, concerned use than routinely generated Notably, study highlights relationship individuals’ experiences medications their interest testing, underscoring potential personalized address healthcare needs.

Язык: Английский

A United Kingdom nationally representative survey of public attitudes towards pharmacogenomics DOI Creative Commons
Emma Magavern, Gabriel Marengo,

Chujan Sivathasan

и другие.

QJM, Год журнала: 2025, Номер unknown

Опубликована: Янв. 31, 2025

Abstract Background Variation in DNA is known to contribute medication response, impacting both medicine effectiveness and incidence of adverse drug reactions (ADRs). However, clinical implementation pharmacogenomics (PGx) has been slow, the views public are not well understood. Aim To assess UK national attitudes around pharmacogenetics. Design Methods The survey was co-designed with Participant Panel at Genomics England data were collected by National Centre for Social Research, using its nationally representative panel adults. Multivariable logistic regression analyses used analyse relationships between selected reported variables, controlled age sex. Results response rate 58%. Two thousand seven hundred nineteen responses obtained. Most respondents (59%) had experienced either no benefit or a side effect. Forty-five per cent having 46% effect, female more likely be groups (P < 0.0001). Despite variability interindividual being understood (89%), involvement predicting risk effect (understood 52% 48%, respectively). Eighty-nine would complete PGx test, 91% wanting direct access this information. Eighty-five adults think that NHS should offer those regularly taking many medicines. Respondents worried overall about misuse compared other routine medical data. Experience prescription impacted on who prescribed almost twice as want test any reason. Conclusion experience working them ADRs. There high level understanding variable but relatively low awareness role genetics plays variability. have results, form testing. Importantly, concerned use than routinely generated Notably, study highlights relationship individuals’ experiences medications their interest testing, underscoring potential personalized address healthcare needs.

Язык: Английский

Процитировано

0